DNMT1 and myelodysplastic syndrome: Likewise, via a genomics-informed computation biology platform recently developed to predict responses to HMAs in 18 patients with MDS/AML, the authors found that gain-of-function mutations in EZH2 and IDH1/2 were predictors of the response to the CpG-methylating effects of azacytidine via DNMT1 inhibition [22].